Related Experiment Video

Updated: May 24, 2025

Characterization of Cell Membrane Extensions and Studying Their Roles in Cancer Cell Adhesion Dynamics
08:11

Characterization of Cell Membrane Extensions and Studying Their Roles in Cancer Cell Adhesion Dynamics

Published on: March 26, 2018

7.6K

RPL22L1 fosters malignant features of cervical cancer via the modulation of DUSP6-ERK axis

Dongmei Zhang1,2,3, Meiqi Zhao1,2, Ping Jiang1,2

  • 1Laboratory of Medical Genetics, Harbin Medical University, Harbin, 150081, China.

Journal of Translational Medicine
|February 28, 2025
PubMed
Abstract

Insights

Ribosomal L22-like 1 (RPL22L1) promotes cervical cancer progression and Sorafenib resistance by activating the ERK pathway. Targeting RPL22L1 with ERK inhibitors offers a potential new therapy for cervical cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Cervical cancer is a significant global health issue requiring novel prognostic markers and targeted therapies.
  • Investigating ribosomal L22-like 1 (RPL22L1) as a potential molecular target for cervical cancer prognosis and treatment.

Purpose of the Study:

  • To elucidate the role and mechanisms of RPL22L1 in cervical cancer.
  • To explore RPL22L1's potential for prognosis assessment and targeted molecular therapies.

Main Methods:

  • Analysis of RPL22L1 expression in cervical cancer cohorts, tissue microarrays, and clinical specimens.
  • In vitro and in vivo functional and molecular biology studies using cell and mouse models.

Main Results:

  • RPL22L1 overexpression correlates with advanced cervical cancer stages, recurrence, and poor prognosis.
  • RPL22L1 promotes cancer cell proliferation, migration, invasion, tumorigenicity, and Sorafenib resistance.
  • RPL22L1 activates the ERK pathway by competitively binding to DUSP6, leading to ERK hyperactivation.

Conclusions:

  • RPL22L1 drives cervical cancer malignancy via DUSP6-mediated ERK pathway activation.
  • Combined therapy with Sorafenib and ERK inhibitors shows promise for RPL22L1-high cervical cancer.
Keywords:
Cervical cancerERKRPL22L1Sorafenib

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.2K
Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer04:20

Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer

Published on: February 9, 2024

857

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.1K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
3.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
4.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K